Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC for Articular Cartilage Defect of Knee
NCT02291926Phase 1Completed
- Sponsor
- Shenzhen Hornetcorn Biotechnology Co., Ltd.
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in osteoarthritis (OA) and Articular cartilage defect, sponsored by Shenzhen Hornetcorn Biotechnology Co., Ltd. Primary endpoint: Severity of adverse events at 12 months. Started Dec 2014; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
osteoarthritis (OA)Articular cartilage defect
Beyond the preview
Go deeper on NCT02291926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291926.